In this on-demand activity, Deepthy Varghese, MSN, ACNP, FNP, Northside Hospital is joined by Sirena Bridges, MSN, FNP-BC, CCDS, VA Tennessee Valley Healthcare, and Jodie L. Hurwitz, MD, FHRS, North Texas Heart Center to discuss the effects of metoprolol and carvedilol on the risk of atrial tachyarrhythmia (ATA) and ventricular arrhythmia (VA) in over 4,000 heart failure (HF) patients with a primary prevention implantable cardioverter-defibrillator (ICD) by pooling data from five landmark ICD trials. Carvedilol treatment was associated with a 35% reduction in the risk of ATA and a corresponding decrease in the risk of inappropriate ICD shocks when compared to metoprolol. While there was a trend towards a lower risk of fast VA with carvedilol, this finding did not reach statistical significance. Carvedilol’s unique properties, including its ability to block both and receptors, improve hemodynamics, and exhibit antiarrhythmic effects, may contribute to its superior outcomes. Overall, these results suggest that carvedilol may be preferred as the first-line beta-blocker choice in HF patients with a primary prevention ICD, but further prospective studies are needed to validate these findings and assess the impact of contemporary HF therapies on arrhythmic outcomes.
- Provider:Heart Rhythm Society
- Activity Link: https://www.heartrhythm365.org/URL/TheLeadEpisode69
- Start Date: 2024-07-09 05:00:00
- End Date: 2024-07-09 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.25 hours
- MOC Credit Details: ABIM - 0.25 Point; Credit Type(s): Medical Knowledge (ABIM)
ABP - 0.25 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Clinical Cardiac Electrophysiology, Pediatric Cardiology